背景:COVID-19大流行对医疗保健系统产生了深远的影响,并减少了获得护理的机会。这项研究分析了在一个法国综合癌症中心,COVID-19大流行在2年内对乳腺癌管理的中期影响。
方法:我们执行,在法国综合癌症中心,一项观察性研究,包括2019年至2021年间所有新诊断的乳腺癌患者。我们收集了乳腺癌的首次咨询数量,乳房和腋窝手术的数量,pTNM和ypTNM癌症分期,治疗顺序(手术或新辅助化疗作为主要治疗),病人的年龄和居住地。
结果:总计,14,772名患者进行了首次乳腺癌咨询。在这9058例乳房和腋窝手术中,1798例患者接受新辅助化疗作为主要治疗。在第一次COVID-19封锁期间(2020年3月17日至2020年5月10日),我们观察到乳腺癌和乳腺癌手术的首次咨询数量分别减少了42.3%和27%的变化率。随后,我们观察到,与2019年相比,2021年初的磋商和手术恢复,略有增加。此外,我们在治疗顺序方面没有发现任何差异,pTNM和ypTNM阶段,2019年参考年至2020年至2021年之间的诊断年龄或居住地。
结论:我们的研究表明,在2020年的第一次封锁期间,活动减少,然后恢复活动。这些令人放心的结果仅涉及乳腺癌患者,并且特定于我们的机构,其肿瘤活性在COVID-19大流行期间得到保留。
BACKGROUND: The COVID-19 pandemic had a profound impact on health-care systems and reduced access to care. This study assays the mid-term effects of the COVID-19 pandemic on breast cancer management over a 2-year-period in a single French Comprehensive Cancer Center.
METHODS: We performed, in a French comprehensive cancer center, an observational study including all patients with newly diagnosed breast cancer between 2019 and 2021. We collected the number of first consultations for breast cancer, the number of breast and axillary surgeries, pTNM and ypTNM cancer staging, the therapeutic sequence (surgery or neoadjuvant chemotherapy as a primary treatment), patients\' age and their place of residence.
RESULTS: In total, 14,772 patients had a first consultation for breast cancer. Among these 9058 breast and axillary surgeries were performed, 1798 patients had neoadjuvant chemotherapy as a primary treatment. During the first COVID-19 lockdown ( March17, 2020-May 10, 2020), we observed a reduction in the number of first consultations for breast cancer and breast cancer surgeries giving respectively a 42.3% and 27% rate of change. Subsequently, we observed a resumption of consultations and surgeries with a slight increase in early 2021 compared to 2019. In addition, we did not find any difference in terms of therapeutic sequence, pTNM and ypTNM stages, age at diagnosis or place of residence between the reference year 2019 and the years 2020 and 2021.
CONCLUSIONS: Our study shows a decrease in activity during the first lockdown of 2020, then a resumption of activity. These reassuring results only concern patients with breast cancer, and are specific to our institution, whose oncology activity was preserved during the COVID-19 pandemic.